Morepen Laboratories Limited (MOREPENLAB.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹132.50 (+4.83%) as of
Key statistics
- Market cap
- 72.60B
- P/E (TTM)
- 74.02
- EPS (TTM)
- 1.79
- Dividend yield
- 0.51%
- 52-week range
- 33.47 – 132.70
- Beta
- 0.54
- Revenue (TTM)
- 17.56B
- Profit margin
- 5.71%
- Volume
- 1.34M
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Gurugram, India
- Employees
- 1,814
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.